Thyroid hormone-like effects without thyrotoxicosis during one year's therapy with NA-DT3 for hypercholesterolemia

Area of Science:

• Endocrinology
• Metabolic Disorders
• Pharmacology

Background:

• Hyperlipidemia is a significant risk factor for cardiovascular disease.
• Thyroid hormones play a crucial role in regulating lipid metabolism.
• Existing treatments for hyperlipidemia have limitations and side effects.

Purpose of the Study:

• To evaluate the efficacy of sodium dextro-triiodothyronine (NaDT3) in reducing serum cholesterol levels in hyperlipidemic adults.
• To assess the impact of NaDT3 on other lipid parameters, including phospholipids and triglycerides.
• To investigate the safety profile and potential side effects of NaDT3 treatment.

Main Methods:

• A clinical study involving 26 hyperlipidemic adults.
• Administration of NaDT3 at a dosage of 1 mg/day for 1 or 2 years.
• Monitoring of serum cholesterol, phospholipids, triglycerides, body weight, blood pressure, and pulse rate.
• Assessment of biochemical changes associated with thyroid hormone activity.

Main Results:

• NaDT3 significantly decreased serum cholesterol levels by approximately 30%.
• Less sustained decreases were observed in serum phospholipids, with occasional lowering of serum triglycerides.
• No significant effects on body weight, blood pressure, or pulse rate were noted.
• Observed biochemical changes were consistent with NaDT3's thyroid hormone activity, distinct from clinical thyrotoxicosis.

Conclusions:

• NaDT3 demonstrates significant potential as a cholesterol-lowering agent in hyperlipidemic individuals.
• The therapeutic effects of NaDT3 appear to be mediated by mechanisms separate from those causing clinical thyrotoxicosis.
• Further research is warranted to fully elucidate the therapeutic applications and long-term safety of NaDT3.